1
|
Tian B, Hua S, Liu J. Multi-functional chitosan-based nanoparticles for drug delivery: Recent advanced insight into cancer therapy. Carbohydr Polym 2023; 315:120972. [PMID: 37230614 DOI: 10.1016/j.carbpol.2023.120972] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2023] [Revised: 04/26/2023] [Accepted: 04/29/2023] [Indexed: 05/27/2023]
Abstract
Cancer therapy continues to be a major global concern, with conventional treatments suffering from low efficacy, untargeted drug delivery, and severe side effects. Recent research in nanomedicine suggests that nanoparticles' unique physicochemical properties can be leveraged to surmount the limitations of conventional cancer treatment. Chitosan-based nanoparticles have gained significant attention due to their high drug-carrying capacity, non-toxicity, biocompatibility, and long circulation time. Chitosan is utilized in cancer therapies as a carrier to accurately deliver active ingredients to tumor sites. This review focuses on clinical studies and current market offerings of anticancer drugs. The unique nature of tumor microenvironments presents new opportunities for the development of smart drug delivery systems, and this review explores the design and preparation of chitosan-based smart nanoparticles. Further, we discuss the therapeutic efficacies of these nanoparticles based on various in vitro and in vivo findings. Finally, we present a forward-looking perspective on the challenges and prospects of chitosan-based nanoparticles in cancer therapy, intending to provide fresh ideas for advancing cancer treatment strategies.
Collapse
Affiliation(s)
- Bingren Tian
- Institute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, China; Key Laboratory of Ningxia Stem Cell and Regenerative Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, China.
| | - Shiyao Hua
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao
| | - Jiayue Liu
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao.
| |
Collapse
|
2
|
Oral docetaxel delivery with cationic polymeric core-shell nanocapsules: In vitro and in vivo evaluation. J Drug Deliv Sci Technol 2023. [DOI: 10.1016/j.jddst.2023.104163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
3
|
Khuroo T, Atifa U, Khuroo A, Mirza MA, Ali A, Iqbal Z. Simultaneous estimation of Paclitaxel and Erlotinib in plasma by liquid chromatography/(+) electrospray tandem mass spectrometry: Application in formulation development and pharmacokinetics. Drug Dev Ind Pharm 2022; 48:292-300. [PMID: 35913109 DOI: 10.1080/03639045.2022.2108830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The bio-analytical method was developed and validated for simultaneous detection and quantification of paclitaxel (PAC) and erlotinib (ERL) in plasma samples. The sample preparation process was accomplished by liquid -liquid extraction technique. The dried and reconstituted samples were subjected to chromatography on Discovery -C18 (50 × 4.6 × 5µm) column and a mobile phase, composed of a mixture of 0.1% formic acid in water: acetonitrile (70:30, v/v), in isocratic mode at a flow rate of 0.6 mL/min. Liquid chromatography coupled to tandem mass spectrometry detection in positive ion mode was selected to provide optimal selectivity and sensitivity. The mass transitions of erlotinib, erlotinib13C6, Paclitaxel and docetaxel were m/z 394.5→278.4, m/z 400.4→284.5, m/z 876.6→308.4 and m/z 830.0→304.0 respectively. The linearity in the calibration curves were obtained in the concentration range of 3.6 -1006.7 ng/ml (r ≥ 0.99) for erlotinib and 5.3 -1500.0 ng/mL for paclitaxel with a LLOQ (lower limit of quantification) of 3.6 and 5.3ng/ml respectively. The run time was achieved in 2.5 minutes only, for all the analytes.
Collapse
Affiliation(s)
- Tahir Khuroo
- Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Texas A&M University, College Station, Texas, 77843, USA.,Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, Hamdard Nagar New Delhi-110062, India.,Department of Clinical Pharmacology and Pharmacokinetics, Sun Pharma, HSIDC, GP-5, Old Delhi Gurgaon Road, Udyog Vihar Industrial Area, Gurgaon 122015, Haryana, India
| | - Umme Atifa
- Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, Hamdard Nagar New Delhi-110062, India
| | - Arshad Khuroo
- Department of Clinical Pharmacology and Pharmacokinetics, Sun Pharma, HSIDC, GP-5, Old Delhi Gurgaon Road, Udyog Vihar Industrial Area, Gurgaon 122015, Haryana, India
| | - Mohd Aamir Mirza
- Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, Hamdard Nagar New Delhi-110062, India
| | - Asgar Ali
- Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, Hamdard Nagar New Delhi-110062, India
| | - Zeenat Iqbal
- Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, Hamdard Nagar New Delhi-110062, India
| |
Collapse
|
4
|
Zhang JY, Liu XX, Lin JY, Bao XY, Peng JQ, Gong ZP, Luan X, Chen Y. Biomimetic engineered nanocarriers inspired by viruses for oral-drug delivery. Int J Pharm 2022; 624:121979. [DOI: 10.1016/j.ijpharm.2022.121979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2022] [Revised: 06/20/2022] [Accepted: 06/30/2022] [Indexed: 10/17/2022]
|
5
|
Parodi A, Buzaeva P, Nigovora D, Baldin A, Kostyushev D, Chulanov V, Savvateeva LV, Zamyatnin AA. Nanomedicine for increasing the oral bioavailability of cancer treatments. J Nanobiotechnology 2021; 19:354. [PMID: 34717658 PMCID: PMC8557561 DOI: 10.1186/s12951-021-01100-2] [Citation(s) in RCA: 32] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Accepted: 10/21/2021] [Indexed: 12/28/2022] Open
Abstract
Abstract Oral administration is an appealing route of delivering cancer treatments. However, the gastrointestinal tract is characterized by specific and efficient physical, chemical, and biological barriers that decrease the bioavailability of medications, including chemotherapeutics. In recent decades, the fields of material science and nanomedicine have generated several delivery platforms with high potential for overcoming multiple barriers associated to oral administration. This review describes the properties of several nanodelivery systems that improve the bioavailability of orally administered therapeutics, highlighting their advantages and disadvantages in generating successful anticancer oral nanomedicines. Graphical Abstract ![]()
Collapse
Affiliation(s)
- Alessandro Parodi
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991, Moscow, Russia. .,Sirius University of Science and Technology, 1 Olympic Ave, 354340, Sochi, Russia.
| | - Polina Buzaeva
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991, Moscow, Russia
| | - Daria Nigovora
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991, Moscow, Russia
| | - Alexey Baldin
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992, Moscow, Russia
| | - Dmitry Kostyushev
- Sirius University of Science and Technology, 1 Olympic Ave, 354340, Sochi, Russia.,National Medical Research Center of Tuberculosis and Infectious Diseases, Ministry of Health, 127994, Moscow, Russia
| | - Vladimir Chulanov
- Sirius University of Science and Technology, 1 Olympic Ave, 354340, Sochi, Russia.,National Medical Research Center of Tuberculosis and Infectious Diseases, Ministry of Health, 127994, Moscow, Russia.,Department of Infectious Diseases, Sechenov University, 119991, Moscow, Russia
| | - Lyudmila V Savvateeva
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991, Moscow, Russia
| | - Andrey A Zamyatnin
- Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 119991, Moscow, Russia. .,Sirius University of Science and Technology, 1 Olympic Ave, 354340, Sochi, Russia. .,Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119992, Moscow, Russia. .,Faculty of Health and Medical Sciences, University of Surrey, Guildford, GU2 7X, UK.
| |
Collapse
|
6
|
Wright L, Barnes TJ, Prestidge CA. Oral delivery of protein-based therapeutics: Gastroprotective strategies, physiological barriers and in vitro permeability prediction. Int J Pharm 2020; 585:119488. [PMID: 32504774 DOI: 10.1016/j.ijpharm.2020.119488] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2020] [Revised: 05/26/2020] [Accepted: 05/28/2020] [Indexed: 02/08/2023]
Abstract
The number of biological molecules emerging as therapeutics is growing exponentially due to their higher specificity and tolerability profiles compared to small molecules. Despite this, their traditionally parenteral delivery often results in poor patient compliance and incomplete treatment. Current research is focussed on developing effective oral delivery strategies to facilitate administration of these biomolecules, however no universal method exists to simultaneously provide gastric protection as well as enhance transport across the gastrointestinal epithelium. Furthermore, for efficient formulation development it is imperative that we can reliably analyse permeability of biomolecules through the gastrointestinal tract, highlighting the importance of the continual development and ongoing evaluation of in vitro predictive permeability tools. Here, we review the physiological obstacles associated with peptide and protein delivery throughout the gastrointestinal tract. Furthermore, we highlight methods utilised to circumvent these barriers and promote improved intestinal permeability. Lastly, we explore in vitro models employed to predict epithelial transport. Key findings highlight the need to carefully understand gastrointestinal physiology, allowing specific engineering of oral delivery systems for biomolecules. Significant importance is placed upon understanding enzymatic degradation susceptibility as well as uptake mechanisms for particulate and protein-based therapeutics for the development of successful oral protein delivery platforms.
Collapse
Affiliation(s)
- Leah Wright
- School of Pharmacy and Medical Science, University of South Australia, 5001, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, UniSA, Australia
| | - Timothy J Barnes
- School of Pharmacy and Medical Science, University of South Australia, 5001, Australia
| | - Clive A Prestidge
- School of Pharmacy and Medical Science, University of South Australia, 5001, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, UniSA, Australia.
| |
Collapse
|
7
|
Santos AC, Costa D, Ferreira L, Guerra C, Pereira-Silva M, Pereira I, Peixoto D, Ferreira NR, Veiga F. Cyclodextrin-based delivery systems for in vivo-tested anticancer therapies. Drug Deliv Transl Res 2020; 11:49-71. [PMID: 32441011 DOI: 10.1007/s13346-020-00778-5] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Cyclodextrins (CDs) are naturally occurring macromolecules widely used as excipients on pharmaceutical formulations, evidencing a large spectrum of applications in the pharmaceutical industry. Their unique ability to act as molecular containers by entrapping a wide range of guest molecules in their internal cavity makes them a remarkable excipient to improve drug apparent solubility, stability, and bioavailability, and a valuable tool for the assembly of new drug delivery systems. These features are especially useful when it comes to chemotherapy, as most of the anticancer drugs present both low permeability and reduced water solubility. Therefore, guest-host inclusion complexes offer several potential advantages not only regarding the improvement of pharmaceutical formulations characteristics but also considering the reduction of drug toxic side effects. The combination of CDs with additional technologies and materials constitutes a potential strategy towards the development of advanced and multifunctional CD-based delivery systems. Paclitaxel, curcumin, camptothecin, doxorubicin, and cisplatin are among the most studied molecules with anticancer activities and have been successfully incorporated in such nanosystems. Exciting results using CDs and CD-based delivery systems have been obtained so far, paving the way towards the attainment of intelligent delivery systems to possibly address cancer therapeutics' unmet needs. In this review, a comprehensive exposition concerning in vivo-tested CD and CD-based delivery systems for anticancer therapy is undertaken. Additionally, the authors address the multivalent functionalities of CD-based delivery systems, namely the incorporation of active target ligands, stimuli-responsiveness components, surface functionalization, or further associations with other delivery systems, aiming at improved in vivo anticancer therapies. Graphical abstract.
Collapse
Affiliation(s)
- Ana Cláudia Santos
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Azinhaga Sta. Comba, 3000-548, Coimbra, Portugal.
- REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Azinhaga Sta. Comba, 3000-548, Coimbra, Portugal.
| | - Diana Costa
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Azinhaga Sta. Comba, 3000-548, Coimbra, Portugal
| | - Laura Ferreira
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Azinhaga Sta. Comba, 3000-548, Coimbra, Portugal
| | - Catarina Guerra
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Azinhaga Sta. Comba, 3000-548, Coimbra, Portugal
| | - Miguel Pereira-Silva
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Azinhaga Sta. Comba, 3000-548, Coimbra, Portugal
| | - Irina Pereira
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Azinhaga Sta. Comba, 3000-548, Coimbra, Portugal
- REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Azinhaga Sta. Comba, 3000-548, Coimbra, Portugal
| | - Diana Peixoto
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Azinhaga Sta. Comba, 3000-548, Coimbra, Portugal
| | - Nuno R Ferreira
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Azinhaga Sta. Comba, 3000-548, Coimbra, Portugal
| | - Francisco Veiga
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Azinhaga Sta. Comba, 3000-548, Coimbra, Portugal
- REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Azinhaga Sta. Comba, 3000-548, Coimbra, Portugal
| |
Collapse
|
8
|
Physico-Chemically Distinct Nanomaterials Synthesized from Derivates of a Poly(Anhydride) Diversify the Spectrum of Loadable Antibiotics. NANOMATERIALS 2020; 10:nano10030486. [PMID: 32182677 PMCID: PMC7153258 DOI: 10.3390/nano10030486] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/17/2020] [Revised: 03/03/2020] [Accepted: 03/06/2020] [Indexed: 12/11/2022]
Abstract
Recent advances in the field of nanotechnology such as nanoencapsulation offer new biomedical applications, potentially increasing the scope and efficacy of therapeutic drug delivery. In addition, the discovery and development of novel biocompatible polymers increases the versatility of these encapsulating nanostructures, enabling chemical properties of the cargo and vehicle to be adapted to specific physiological requirements. Here, we evaluate the capacity of various polymeric nanostructures to encapsulate various antibiotics of different classes, with differing chemical structure. Polymers were sourced from two separate derivatives of poly(methyl vinyl ether-alt-maleic anhydride) (PMVE/MA): an acid (PMVE/MA-Ac) and a monoethyl ester (PMVE/MA-Es). Nanoencapsulation of antibiotics was attempted through electrospinning, and nanoparticle synthesis through solvent displacement, for both polymers. Solvent incompatibilities prevented the nanoencapsulation of amikacin, neomycin and ciprofloxacin in PMVE/MA-Es nanofibers. However, all compounds were successfully loaded into PMVE/MA-Es nanoparticles. Encapsulation efficiencies in nanofibers reached approximately 100% in all compatible systems; however, efficiencies varied substantially in nanoparticles systems, depending on the tested compound (14%-69%). Finally, it was confirmed that both these encapsulation processes did not alter the antimicrobial activity of any tested antibiotic against Staphylococcus aureus and Escherichia coli, supporting the viability of these approaches for nanoscale delivery of antibiotics.
Collapse
|
9
|
Babadi D, Dadashzadeh S, Osouli M, Daryabari MS, Haeri A. Nanoformulation strategies for improving intestinal permeability of drugs: A more precise look at permeability assessment methods and pharmacokinetic properties changes. J Control Release 2020; 321:669-709. [PMID: 32112856 DOI: 10.1016/j.jconrel.2020.02.041] [Citation(s) in RCA: 49] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2019] [Revised: 02/25/2020] [Accepted: 02/25/2020] [Indexed: 12/12/2022]
Abstract
The therapeutic efficacy of orally administered drugs is often restricted by their inherent limited oral bioavailability. Low water solubility, limited permeability through the intestinal barrier, instability in harsh environment of the gastrointestinal (GI) tract and being substrate of the efflux pumps and the cytochrome P450 (CYP) can impair oral drug bioavailability resulting in erratic and variable plasma drug profile. As more drugs with low membrane permeability are developed, new interest is growing to enhance their intestinal permeability and bioavailability. A wide variety of nanosystems have been developed to improve drug transport and absorption. Sufficient evidence exists to suggest that nanoparticles are able to increase the transepithelial transport of drug molecules. However, key questions remained unanswered. What types of nanoparticles are more efficient? What are preclinical (or clinical) achievements of each type of nanoformulation in terms of pharmacokinetic (PK) parameters? Addressing this issue in this paper, we have reviewed the current literature regarding permeability enhancement, permeability assessment methods and changes in PK parameters following administration of various nanoformulations. Although permeability enhancement by various nanoformulations holds great promise for oral drug delivery, many challenges still need to be addressed before development of more clinically successful nanoproducts.
Collapse
Affiliation(s)
- Delaram Babadi
- Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Simin Dadashzadeh
- Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mahraz Osouli
- Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | | | - Azadeh Haeri
- Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
10
|
Mucoadhesive paclitaxel-loaded chitosan-poly (isobutyl cyanoacrylate) core-shell nanocapsules containing copaiba oil designed for oral drug delivery. J Drug Deliv Sci Technol 2019. [DOI: 10.1016/j.jddst.2019.101194] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
11
|
Breaking the barricade of oral chemotherapy through polysaccharide nanocarrier. Int J Biol Macromol 2019; 130:34-49. [DOI: 10.1016/j.ijbiomac.2019.02.094] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2018] [Revised: 02/10/2019] [Accepted: 02/15/2019] [Indexed: 01/19/2023]
|
12
|
Pramanik A, Garg S. Design of diffusion-controlled drug delivery devices for controlled release of Paclitaxel. Chem Biol Drug Des 2019; 94:1478-1487. [PMID: 30920732 DOI: 10.1111/cbdd.13524] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2018] [Revised: 03/18/2019] [Accepted: 03/20/2019] [Indexed: 12/12/2022]
Abstract
Controlled drug delivery devices were predicted in a reverse engineering framework for the controlled release of Paclitaxel, an anti-cancer drug, widely used in the treatment of solid tumors. Using quantitative structure-property relationship models for mutual diffusion coefficients of the drug in biocompatible and biodegradable polymers and partition coefficients of the drug between polymers and blood, a framework was developed to predict optimal drug delivery devices for desired dosage regimens. The validation of the predicted mutual diffusion and partition coefficients using experimental data was reported in previous studies. Optimal design parameters along with selection of most appropriate polymers suitable for different dosage regimens, selected based on current clinical practice, were predicted for maximum bioavailability of the drug while maintaining the released drug concentration in blood within the therapeutic range. Reservoir and monolithic type of diffusion-controlled drug delivery devices of different shapes and sizes were predicted with different initial drug loadings and bioavailability for different dosage regimens. The effects of the released Paclitaxel from these devices on the tumor growth were also modeled using a previously reported mathematical pharmacokinetic-pharmacodynamic model. The proposed approach can easily be used to design other diffusion-controlled drug delivery devices.
Collapse
Affiliation(s)
- Anurag Pramanik
- Department of Chemical Engineering, Indian Institute of Technology Kanpur, Kanpur, India
| | - Sanjeev Garg
- Department of Chemical Engineering, Indian Institute of Technology Kanpur, Kanpur, India
| |
Collapse
|
13
|
Ali I, Shah MR, Yousuf S, Ahmed S, Shah K, Javed I. Hemolytic and cellular toxicology of a sulfanilamide-based nonionic surfactant: a niosomal carrier for hydrophobic drugs. Toxicol Res (Camb) 2018; 7:771-778. [PMID: 30310655 DOI: 10.1039/c8tx00108a] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2018] [Accepted: 06/12/2018] [Indexed: 01/29/2023] Open
Abstract
Biocompatible surfactants are of diverse pharmaceutical interest due to their ability to self-assemble into nano-particulate systems which can be used for single-step drug loading, based upon the hydrophobic-hydrophobic interaction between a hydrophobic drug and the lipophilic part of a surfactant molecule. However, surfactants are associated with cytotoxicity and hemolysis due to their amphiphilic interaction with cellular membranes. This study reports a novel membrane-compatible surfactant, synthesized from sulfanilamide and its self-micellization into niosomes. The surfactant was synthesized in a single step reaction via the introduction of an alkyl chain in the sulfanilamide moiety by conjugation with deconyl chloride. The synthesized surfactant (S-SDC) was characterized by 1H and 13C NMR, mass spectrometry and single crystal XRD. The S-SDC niosomes were explored for drug delivery with clarithromycin as a model drug. The biocompatibility of the surfactant was investigated through hemolysis and cytotoxicity. The surfactant presented a very low critical micellar concentration (CMC) of 0.04 mM and entrapped 65% of the drug which was released in a sustained manner, over 12 h, at acidic and physiological pH. The vesicles were spherical in shape with 234 ± 3.61 nm mean diameter and a narrow size distribution. Niosomes were hemocompatible and nontoxic to cellular membrane. The results suggested the sulfanilamide based surfactant can be applied as a novel and cell membrane compatible niosomal drug delivery vehicle.
Collapse
Affiliation(s)
- Imdad Ali
- H.E.J. Research Institute of Chemistry , International Center for Chemical and Biological Sciences , University of Karachi , Karachi 74200 , Pakistan .
| | - Muhammad Raza Shah
- H.E.J. Research Institute of Chemistry , International Center for Chemical and Biological Sciences , University of Karachi , Karachi 74200 , Pakistan .
| | - Sammer Yousuf
- H.E.J. Research Institute of Chemistry , International Center for Chemical and Biological Sciences , University of Karachi , Karachi 74200 , Pakistan .
| | - Shakil Ahmed
- H.E.J. Research Institute of Chemistry , International Center for Chemical and Biological Sciences , University of Karachi , Karachi 74200 , Pakistan .
| | - Kiramat Shah
- H.E.J. Research Institute of Chemistry , International Center for Chemical and Biological Sciences , University of Karachi , Karachi 74200 , Pakistan .
| | - Ibrahim Javed
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology , Monash Institute of Pharmaceutical Sciences , Monash University , 381 Royal Parade , Parkville , Victoria 3052 , Australia .
| |
Collapse
|
14
|
Nothnagel L, Wacker MG. How to measure release from nanosized carriers? Eur J Pharm Sci 2018; 120:199-211. [PMID: 29751101 DOI: 10.1016/j.ejps.2018.05.004] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Revised: 04/13/2018] [Accepted: 05/07/2018] [Indexed: 12/28/2022]
Abstract
Novel drug delivery systems exhibit great potential in the formulation of poorly soluble compounds but have also been applied to reduce side effects of highly active drug molecules. Despite all efforts, there are only few technologies available to investigate the in vitro release of next-generation nanotherapeutics. In the following, different approaches for testing the drug release from nanoparticles in the fields of formulation development and quality control will be discussed. A variety of methods is available, starting from dialysis-based equipment, in situ measurements, flow-through devices and sample and separate setups. If possible, these methods should enable a more rapid formulation development and quality control of nanosized carriers as well as improve the prediction of in vivo performance and clinical outcomes.
Collapse
Affiliation(s)
- Lisa Nothnagel
- Department of Pharmaceutical Technology and Nanosciences, Fraunhofer-Institute for Molecular Biology and Applied Ecology (IME), 60438 Frankfurt am Main, Germany
| | - Matthias G Wacker
- Department of Pharmaceutical Technology and Nanosciences, Fraunhofer-Institute for Molecular Biology and Applied Ecology (IME), 60438 Frankfurt am Main, Germany; Institute of Pharmaceutical Technology, Goethe University, 60438 Frankfurt am Main, Germany.
| |
Collapse
|
15
|
Mira A, Mateo CR, Mallavia R, Falco A. Poly(methyl vinyl ether-alt-maleic acid) and ethyl monoester as building polymers for drug-loadable electrospun nanofibers. Sci Rep 2017; 7:17205. [PMID: 29222482 PMCID: PMC5722912 DOI: 10.1038/s41598-017-17542-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Accepted: 11/24/2017] [Indexed: 12/19/2022] Open
Abstract
New biomaterials are sought for the development of bioengineered nanostructures. In the present study, electrospun nanofibers have been synthesized by using poly(methyl vinyl ether-alt-maleic acid) and poly(methyl vinyl ether-alt-maleic ethyl monoester) (PMVEMA-Ac and PMVEMA-ES, respectively) as building polymers for the first time. To further functionalize these materials, nanofibers of PMVEMA-Ac and PMVEMA-ES containing a conjugated polyelectrolyte (HTMA-PFP, blue emitter, and HTMA-PFNT, red emitter) were achieved with both forms maintaining a high solid state fluorescence yield without altered morphology. Also, 5-aminolevulinic acid (5-ALA) was incorporated within these nanofibers, where it remained chemically stable. In all cases, nanofiber diameters were less than 150 nm as determined by scanning and transmission electron microscopy, and encapsulation efficiency of 5-ALA was 97 ± 1% as measured by high-performance liquid chromatography. Both polymeric matrices showed rapid release kinetics in vertical cells (Franz cells) and followed Higuchi kinetics. In addition, no toxicity of nanofibers, in the absence of light, was found in HaCaT and SW480 cell lines. Finally, it was shown that loaded 5-ALA was functional, as it was internalized by cells in nanofiber-treated cultures and served as a substrate for the generation of protoporphyrin IX, suggesting these pharmaceutical vehicles are suitable for photodynamic therapy applications.
Collapse
Affiliation(s)
- Amalia Mira
- Universidad Miguel Hernández (UMH), Instituto de Biología Molecular y Celular (IBMC), 03202, Elche (Alicante), Spain
| | - C Reyes Mateo
- Universidad Miguel Hernández (UMH), Instituto de Biología Molecular y Celular (IBMC), 03202, Elche (Alicante), Spain
| | - Ricardo Mallavia
- Universidad Miguel Hernández (UMH), Instituto de Biología Molecular y Celular (IBMC), 03202, Elche (Alicante), Spain.
| | - Alberto Falco
- Universidad Miguel Hernández (UMH), Instituto de Biología Molecular y Celular (IBMC), 03202, Elche (Alicante), Spain.
| |
Collapse
|
16
|
Calleja P, Irache J, Zandueta C, Martínez-Oharriz C, Espuelas S. A combination of nanosystems for the delivery of cancer chemoimmunotherapeutic combinations: 1-Methyltryptophan nanocrystals and paclitaxel nanoparticles. Pharmacol Res 2017; 126:77-83. [DOI: 10.1016/j.phrs.2017.09.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2017] [Revised: 09/05/2017] [Accepted: 09/07/2017] [Indexed: 12/22/2022]
|
17
|
Safety against nephrotoxicity in paclitaxel treatment: Oral nanocarrier as an effective tool in preclinical evaluation with marked in vivo antitumor activity. Regul Toxicol Pharmacol 2017; 91:179-189. [PMID: 29080846 DOI: 10.1016/j.yrtph.2017.10.023] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2016] [Revised: 10/18/2017] [Accepted: 10/22/2017] [Indexed: 12/16/2022]
Abstract
Oral paclitaxel (PTXL) formulations freed from cremophor® EL (CrEL) is always in utmost demand by the cancerous patients due to toxicities associated with the currently marketed formulation. In our previous investigation [Int. J. Pharm. 2014; 460:131], we have developed an oral oil based nanocarrier for the lipophilic drug, PTXL to target bioavailability issue and patient compliance. Here, we report in vivo antitumor activity and 28-day sub-chronic toxicity of the developed PTXL nanoemulsion. It was observed that the apoptotic potential of oral PTXL nanoemulsion significantly inhibited the growth of solid tumor (59.2 ± 7.17%; p < 0.001) without causing any explicit toxicity. The 6.5 mg/kg and 3 mg/kg oral PTXL nanoemulsion dose did not cause any notable alteration in haematological, biochemical/structural characteristics during 28-day sub-chronic toxicity studies in the experimental mice. Whereas, the toxicity of 12.8 mg/kg body weight dose showed decrease in RBC, haemoglobin and neutrophil counts. In contrast, marketed PTXL (Taxol®) was found to be comparatively more toxic to the experimental animals. Taxol® treatment resulted glomerulonephritis in histopathological examination, which could be correlated with increased level of creatinine and associated nephrotoxicity. This investigations conclude that the developed oral nanoemulsion presents a viable therapeutics bio-system to step towards clinical application as well as substitute CrEL based PTXL formulations.
Collapse
|
18
|
Geetha Bai R, Muthoosamy K, Shipton FN, Manickam S. Acoustic cavitation induced generation of stabilizer-free, extremely stable reduced graphene oxide nanodispersion for efficient delivery of paclitaxel in cancer cells. ULTRASONICS SONOCHEMISTRY 2017; 36:129-138. [PMID: 28069192 DOI: 10.1016/j.ultsonch.2016.11.021] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/07/2016] [Revised: 11/14/2016] [Accepted: 11/14/2016] [Indexed: 06/06/2023]
Abstract
Graphene is one of the highly explored nanomaterials due to its unique and extraordinary properties. In this study, by utilizing a hydrothermal reduction method, graphene oxide (GO) was successfully converted to reduced graphene oxide (RGO) without using any toxic reducing agents. Following this, with the use of ultrasonic cavitation, profoundly stable few layer thick RGO nanodispersion was generated without employing any stabilizers or surfactants. During ultrasonication, shockwaves from the collapse of bubbles cause a higher dispersing energy to the graphene nanosheets which surpass the forces of Van der Waal's and π-π stacking and thus pave the way to form a stable aqueous nanodispersion of graphene. Ultrasonication systems with different power intensity have been employed to determine the optimum conditions for obtaining the most stable RGO dispersion. The optimised conditions of ultrasonic treatments led to the development of a very stable reduced graphene oxide (RGO) aqueous dispersion. The stability was observed for two years and was analyzed by using Zetasizer by measuring the particle size and zeta potential at regular intervals and found to have exceptional stability. The excellent stability at physiological pH promotes its utilization in nano drug delivery application as a carrier for Paclitaxel (Ptx), an anticancer drug. The in vitro cytotoxicity analysis of Ptx loaded RGO nanodispersion by MTT assay performed on the cell lines revealed the potential of the nanodispersion as a suitable drug carrier. Studies on normal lung cells, MRC-5 and nasopharyngeal cancer cells, HK-1 supported the biocompatibility of RGO-Ptx towards normal cell line. This investigation shows the potential of exceptionally stable RGO-Ptx nanodispersion in nano drug delivery applications.
Collapse
Affiliation(s)
- Renu Geetha Bai
- Nanotechnology and Advanced Materials (NATAM), Faculty of Engineering, University of Nottingham Malaysia Campus, 43500 Semenyih, Selangor, Malaysia
| | - Kasturi Muthoosamy
- Nanotechnology and Advanced Materials (NATAM), Faculty of Engineering, University of Nottingham Malaysia Campus, 43500 Semenyih, Selangor, Malaysia
| | - Fiona Natalia Shipton
- School of Pharmacy, Faculty of Science, University of Nottingham Malaysia Campus, 43500 Semenyih, Selangor, Malaysia
| | - Sivakumar Manickam
- Nanotechnology and Advanced Materials (NATAM), Faculty of Engineering, University of Nottingham Malaysia Campus, 43500 Semenyih, Selangor, Malaysia.
| |
Collapse
|
19
|
Soundararajan R, Sasaki K, Godfrey L, Odunze U, Fereira N, Schätzlein A, Uchegbu I. Direct in vivo evidence on the mechanism by which nanoparticles facilitate the absorption of a water insoluble, P-gp substrate. Int J Pharm 2017; 514:121-132. [PMID: 27863655 DOI: 10.1016/j.ijpharm.2016.08.013] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2016] [Revised: 08/04/2016] [Accepted: 08/07/2016] [Indexed: 11/18/2022]
Abstract
Here we examine the mechanisms by which nanoparticles enable the oral absorption of water-insoluble, P-glycoprotein efflux pump (P-gp) substrates, without recourse to P-gp inhibitors. Both 200nm paclitaxel N-(2-phenoxyacetyl)-6-O-glycolchitosan (GCPh) nanoparticles (GCPh-PTX) and a simulated Taxol formulation, facilitate drug dissolution in biorelevant media, unlike paclitaxel nanocrystals. Verapamil (40mgkg-1) increased the oral absorption from low dose Taxol (6 or 10mgkg-1) by 100%, whereas the oral absorption from high dose Taxol (20mgkg-1) or low dose GCPh-PTX (6 or 10mgkg-1) was largely unchanged by verapamil. There was virtually no absorption from control paclitaxel nanocrystals (20mgkg-1). Imaging of ex-vivo rat ileum samples showed that fluorescently labelled GCPh nanoparticles are mucoadhesive and are taken up by ileum epithelial cells. GCPh nanoparticles were also found to open Caco-2 cell tight junctions. In conclusion, mucoadhesive, drug solubilising GCPh nanoparticles enable the oral absorption of paclitaxel via the saturation of the P-gp pump (by high local drug concentrations) and by particle uptake and tight junction opening mechanisms.
Collapse
Affiliation(s)
| | - Kenji Sasaki
- UCL School of Pharmacy, University College London, London, UK
| | - Lisa Godfrey
- UCL School of Pharmacy, University College London, London, UK
| | | | - Nancy Fereira
- UCL School of Pharmacy, University College London, London, UK
| | - Andreas Schätzlein
- UCL School of Pharmacy, University College London, London, UK; Nanomerics Ltd., 1394 High Road, London N20 9YZ, UK
| | - Ijeoma Uchegbu
- UCL School of Pharmacy, University College London, London, UK; Nanomerics Ltd., 1394 High Road, London N20 9YZ, UK.
| |
Collapse
|
20
|
Agrawal AK, Aqil F, Jeyabalan J, Spencer WA, Beck J, Gachuki BW, Alhakeem SS, Oben K, Munagala R, Bondada S, Gupta RC. Milk-derived exosomes for oral delivery of paclitaxel. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2017; 13:1627-1636. [PMID: 28300659 DOI: 10.1016/j.nano.2017.03.001] [Citation(s) in RCA: 329] [Impact Index Per Article: 47.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Revised: 02/13/2017] [Accepted: 03/03/2017] [Indexed: 12/11/2022]
Abstract
In this report milk-derived exosomes have been investigated for oral delivery of the chemotherapeutic drug paclitaxel (PAC) as an alternative to conventional i.v. therapy for improved efficacy and reduced toxicity. PAC-loaded exosomes (ExoPAC) were found to have a particle size of ~108 nm, a narrow particle size distribution (PDI ~0.190), zeta potential (~ -7 mV) and a practical loading efficiency of ~8%. Exosomes and ExoPAC exhibited excellent stability in the presence of simulated-gastrointestinal fluids, and during the storage at -80 °C. A sustained release of PAC was also observed up to 48 h in vitro using PBS (pH 6.8). Importantly, ExoPAC delivered orally showed significant tumor growth inhibition (60%; P<0.001) against human lung tumor xenografts in nude mice. Treatment with i.p. PAC at the same dose as ExoPAC, however, showed modest but statistically insignificant inhibition (31%). Moreover, ExoPAC demonstrated remarkably lower systemic and immunologic toxicities as compared to i.v. PAC.
Collapse
Affiliation(s)
- Ashish K Agrawal
- James Graham Brown Cancer Center, University of Louisville, Louisville, KY
| | - Farrukh Aqil
- James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Department of Medicine, University of Louisville, Louisville, KY
| | | | | | | | - Beth W Gachuki
- Department of Microbiology, Immunology & Molecular Genetics, and Markey Cancer Center, University of Kentucky, Lexington, KY
| | - Sara S Alhakeem
- Department of Microbiology, Immunology & Molecular Genetics, and Markey Cancer Center, University of Kentucky, Lexington, KY
| | - Karine Oben
- Department of Microbiology, Immunology & Molecular Genetics, and Markey Cancer Center, University of Kentucky, Lexington, KY
| | - Radha Munagala
- James Graham Brown Cancer Center, University of Louisville, Louisville, KY; Department of Medicine, University of Louisville, Louisville, KY
| | - Subbarao Bondada
- Department of Microbiology, Immunology & Molecular Genetics, and Markey Cancer Center, University of Kentucky, Lexington, KY
| | - Ramesh C Gupta
- James Graham Brown Cancer Center, University of Louisville, Louisville, KY; 3P Biotechnologies, Inc., Louisville, KY; Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY.
| |
Collapse
|
21
|
Iglesias T, Dusinska M, El Yamani N, Irache JM, Azqueta A, López de Cerain A. In vitro evaluation of the genotoxicity of poly(anhydride) nanoparticles designed for oral drug delivery. Int J Pharm 2017; 523:418-426. [PMID: 28286081 DOI: 10.1016/j.ijpharm.2017.03.016] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Revised: 03/07/2017] [Accepted: 03/08/2017] [Indexed: 10/20/2022]
Abstract
In the last years, the development of nanomaterials has significantly increased due to the immense variety of potential applications in technological sectors, such as medicine, pharmacy and food safety. Focusing on the nanodevices for oral drug delivery, poly(anhydride) nanoparticles have received extensive attention due to their unique properties, such as their capability to develop intense adhesive interactions within the gut mucosa, their modifiable surface and their biodegradable and easy-to-produce profile. However, current knowledge of the possible adverse health effects as well as, toxicological information, is still exceedingly limited. Thus, we investigated the capacity of two poly(anhydride) nanoparticles, Gantrez® AN 119-NP (GN-NP) and Gantrez® AN 119 covered with mannosamine (GN-MA-NP), and their main bulk material (Gantrez® AN 119-Polymer), to induce DNA damage and thymidine kinase (TK+/-) mutations in L5178Y TK+/- mouse lymphoma cells after 24h of exposure. The results showed that GN-NP, GN-MA-NP and their polymer did not induce DNA strand breaks or oxidative damage at concentrations ranging from 7.4 to 600μg/mL. Besides, the mutagenic potential of these nanoparticles and their polymer revealed no significant or biologically relevant gene mutation induction at concentrations up to 600μg/mL under our experimental settings. Considering the non-genotoxic effects of GN-NP and GN-MA-NP, as well as their exceptional properties, these nanoparticles are promising nanocarriers for oral medical administrations.
Collapse
Affiliation(s)
- T Iglesias
- Department of Pharmacology and Toxicology, Faculty of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain
| | - M Dusinska
- Health Effects Laboratory, Department of Environmental Chemistry, Norwegian Institute for Air Research, Kjeller, Norway
| | - N El Yamani
- Health Effects Laboratory, Department of Environmental Chemistry, Norwegian Institute for Air Research, Kjeller, Norway
| | - J M Irache
- Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy and Nutrition, University of Navarra, Irunlarrea 1, 31008, Pamplona, Spain
| | - A Azqueta
- Department of Pharmacology and Toxicology, Faculty of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Spain.
| | - A López de Cerain
- Department of Pharmacology and Toxicology, Faculty of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Spain
| |
Collapse
|
22
|
Malhaire H, Gimel JC, Roger E, Benoît JP, Lagarce F. How to design the surface of peptide-loaded nanoparticles for efficient oral bioavailability? Adv Drug Deliv Rev 2016; 106:320-336. [PMID: 27058155 DOI: 10.1016/j.addr.2016.03.011] [Citation(s) in RCA: 66] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2015] [Revised: 03/17/2016] [Accepted: 03/28/2016] [Indexed: 01/22/2023]
Abstract
The oral administration of proteins is a current challenge to be faced in the field of therapeutics. There is currently much interest in nanocarriers since they can enhance oral bioavailability. For lack of a clear definition, the key characteristics of nanoparticles have been highlighted. Specific surface area is one of these characteristics and represents a huge source of energy that can be used to control the biological fate of the carrier. The review discusses nanocarrier stability, mucus interaction and absorption through the intestinal epithelium. The protein corona, which has raised interest over the last decade, is also discussed. The universal ideal surface is a myth and over-coated carriers are not a solution either. Besides, common excipients can be useful on several targets. The suitable design should rather take into account the composition, structure and behavior of unmodified nanomaterials.
Collapse
|
23
|
Lundquist P, Artursson P. Oral absorption of peptides and nanoparticles across the human intestine: Opportunities, limitations and studies in human tissues. Adv Drug Deliv Rev 2016; 106:256-276. [PMID: 27496705 DOI: 10.1016/j.addr.2016.07.007] [Citation(s) in RCA: 310] [Impact Index Per Article: 38.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2016] [Revised: 07/02/2016] [Accepted: 07/08/2016] [Indexed: 12/23/2022]
Abstract
In this contribution, we review the molecular and physiological barriers to oral delivery of peptides and nanoparticles. We discuss the opportunities and predictivity of various in vitro systems with special emphasis on human intestine in Ussing chambers. First, the molecular constraints to peptide absorption are discussed. Then the physiological barriers to peptide delivery are examined. These include the gastric and intestinal environment, the mucus barrier, tight junctions between epithelial cells, the enterocytes of the intestinal epithelium, and the subepithelial tissue. Recent data from human proteome studies are used to provide information about the protein expression profiles of the different physiological barriers to peptide and nanoparticle absorption. Strategies that have been employed to increase peptide absorption across each of the barriers are discussed. Special consideration is given to attempts at utilizing endogenous transcytotic pathways. To reliably translate in vitro data on peptide or nanoparticle permeability to the in vivo situation in a human subject, the in vitro experimental system needs to realistically capture the central aspects of the mentioned barriers. Therefore, characteristics of common in vitro cell culture systems are discussed and compared to those of human intestinal tissues. Attempts to use the cell and tissue models for in vitro-in vivo extrapolation are reviewed.
Collapse
Affiliation(s)
- P Lundquist
- Department of Pharmacy, Uppsala University, Box 580, SE-752 37 Uppsala, Sweden.
| | - P Artursson
- Department of Pharmacy, Uppsala University, Box 580, SE-752 37 Uppsala, Sweden.
| |
Collapse
|
24
|
Duchêne D, Bochot A. Thirty years with cyclodextrins. Int J Pharm 2016; 514:58-72. [DOI: 10.1016/j.ijpharm.2016.07.030] [Citation(s) in RCA: 76] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2016] [Revised: 07/13/2016] [Accepted: 07/15/2016] [Indexed: 01/05/2023]
|
25
|
Liu W, Pan H, Zhang C, Zhao L, Zhao R, Zhu Y, Pan W. Developments in Methods for Measuring the Intestinal Absorption of Nanoparticle-Bound Drugs. Int J Mol Sci 2016; 17:ijms17071171. [PMID: 27455239 PMCID: PMC4964542 DOI: 10.3390/ijms17071171] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2016] [Revised: 07/12/2016] [Accepted: 07/13/2016] [Indexed: 12/17/2022] Open
Abstract
With the rapid development of nanotechnology, novel drug delivery systems comprising orally administered nanoparticles (NPs) have been paid increasing attention in recent years. The bioavailability of orally administered drugs has significant influence on drug efficacy and therapeutic dosage, and it is therefore imperative that the intestinal absorption of oral NPs be investigated. This review examines the various literature on the oral absorption of polymeric NPs, and provides an overview of the intestinal absorption models that have been developed for the study of oral nanoparticles. Three major categories of models including a total of eight measurement methods are described in detail (in vitro: dialysis bag, rat gut sac, Ussing chamber, cell culture model; in situ: intestinal perfusion, intestinal loops, intestinal vascular cannulation; in vivo: the blood/urine drug concentration method), and the advantages and disadvantages of each method are contrasted and elucidated. In general, in vitro and in situ methods are relatively convenient but lack accuracy, while the in vivo method is troublesome but can provide a true reflection of drug absorption in vivo. This review summarizes the development of intestinal absorption experiments in recent years and provides a reference for the systematic study of the intestinal absorption of nanoparticle-bound drugs.
Collapse
Affiliation(s)
- Wei Liu
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China.
- Department of Pharmaceutics, School of Pharmacy, Zhengzhou University, 100 Science Avenue, Zhengzhou 450001, China.
| | - Hao Pan
- School of Pharmacy, Queen's University Belfast, Belfast BT7 1NN, UK.
| | - Caiyun Zhang
- Department of Pharmaceutics, School of Pharmacy, Zhengzhou University, 100 Science Avenue, Zhengzhou 450001, China.
| | - Liling Zhao
- Department of Pharmaceutics, School of Pharmacy, Zhengzhou University, 100 Science Avenue, Zhengzhou 450001, China.
| | - Ruixia Zhao
- Department of Pharmaceutics, School of Pharmacy, Zhengzhou University, 100 Science Avenue, Zhengzhou 450001, China.
| | - Yongtao Zhu
- Department of Pharmaceutics, School of Pharmacy, Zhengzhou University, 100 Science Avenue, Zhengzhou 450001, China.
| | - Weisan Pan
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China.
| |
Collapse
|
26
|
Alshehri SM, Al-Lohedan HA, Chaudhary AA, Al-Farraj E, Alhokbany N, Issa Z, Alhousine S, Ahamad T. Delivery of ibuprofen by natural macroporous sporopollenin exine capsules extracted from Phoenix dactylifera L. Eur J Pharm Sci 2016; 88:158-65. [DOI: 10.1016/j.ejps.2016.02.004] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Revised: 01/19/2016] [Accepted: 02/06/2016] [Indexed: 11/24/2022]
|
27
|
Toward Understanding Drug Release From Biodegradable Polymer Microspheres of Different Erosion Kinetics Modes. J Pharm Sci 2016; 105:1934-1946. [DOI: 10.1016/j.xphs.2016.04.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Revised: 04/01/2016] [Accepted: 04/01/2016] [Indexed: 11/22/2022]
|
28
|
Advances in the transepithelial transport of nanoparticles. Drug Discov Today 2016; 21:1155-61. [PMID: 27196527 DOI: 10.1016/j.drudis.2016.05.007] [Citation(s) in RCA: 51] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2015] [Revised: 04/01/2016] [Accepted: 05/10/2016] [Indexed: 01/06/2023]
Abstract
The intestinal epithelium represents a barrier to the delivery of nanoparticles (NPs). It prevents intact NPs from efficiently crossing the mucosa to access the circulation, thus limiting the successful application of NP-based oral drug delivery. Recent advances in nanotechnology have provided promising solutions to this challenge. This review describes the potential intestinal absorption pathways of NPs, including the transenterocytic pathway, paracellular pathway and M-cell-mediated pathway. NP properties that influence transcytosis are summarized; and the biodistribution of NPs after oral absorption is described and the future prospects of novel NPs are explored.
Collapse
|
29
|
Papst S, Brimble MA, Evans CW, Verdon DJ, Feisst V, Dunbar PR, Tilley RD, Williams DE. Cell-targeted platinum nanoparticles and nanoparticle clusters. Org Biomol Chem 2015; 13:6567-72. [DOI: 10.1039/c5ob00822k] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The facile preparation of cell-targeted platinum nanoparticles (PtNPs) is described, using designed peptides that as a single molecule control PtNP cluster growth, stabilise clusters in aqueous suspension and enable attachment of a versatile range of cell-targeting ligands.
Collapse
Affiliation(s)
- Stefanie Papst
- The MacDiarmid Institute for Advanced Materials and Nanotechnology
- School of Chemical Sciences
- The University of Auckland
- Auckland 1123
- New Zealand
| | - Margaret A. Brimble
- The MacDiarmid Institute for Advanced Materials and Nanotechnology
- School of Chemical Sciences
- The University of Auckland
- Auckland 1123
- New Zealand
| | - Clive W. Evans
- School of Biological Sciences
- The University of Auckland
- Auckland 1123
- New Zealand
| | - Daniel J. Verdon
- School of Biological Sciences
- The University of Auckland
- Auckland 1123
- New Zealand
| | - Vaughan Feisst
- School of Biological Sciences
- The University of Auckland
- Auckland 1123
- New Zealand
| | - P. Rod Dunbar
- School of Biological Sciences
- The University of Auckland
- Auckland 1123
- New Zealand
- Maurice Wilkins Centre
| | - Richard D. Tilley
- The MacDiarmid Institute for Advanced Materials and Nanotechnology
- School of Chemical and Physical Sciences
- Victoria University of Wellington
- New Zealand
| | - David E. Williams
- The MacDiarmid Institute for Advanced Materials and Nanotechnology
- School of Chemical Sciences
- The University of Auckland
- Auckland 1123
- New Zealand
| |
Collapse
|